April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Effective Time Point For Channelrhodopsin-2 mediated Gene Therapy After Photoreceptor Degeneration In Rcs Rats
Author Affiliations & Notes
  • Eriko Sugano
    Int'l Adv Interdisciplinary Res, Tohoku Univ, Sendai, Japan
  • Hitomi Isago
    Int'l Adv Interdisciplinary Res, Tohoku Univ, Sendai, Japan
  • Zhuo Wang
    Int'l Adv Interdisciplinary Res, Tohoku Univ, Sendai, Japan
    Japan Foundation for Aging and Health, Aichi, Japan
  • Namie Murayama
    Int'l Adv Interdisciplinary Res, Tohoku Univ, Sendai, Japan
  • Makoto Tamai
    Tohoku Univ School of Medicine, Sendai, Japan
  • Hiroshi Tomita
    International Adv Interdisciplinary Res, Tohoku University, Sendai, Japan
  • Footnotes
    Commercial Relationships  Eriko Sugano, None; Hitomi Isago, None; Zhuo Wang, None; Namie Murayama, None; Makoto Tamai, None; Hiroshi Tomita, None
  • Footnotes
    Support  NIBIO(10-6); Health, Labour and Welfare of Japan; Ministry of Education (21791664 and 21200022)
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 480. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Eriko Sugano, Hitomi Isago, Zhuo Wang, Namie Murayama, Makoto Tamai, Hiroshi Tomita; Effective Time Point For Channelrhodopsin-2 mediated Gene Therapy After Photoreceptor Degeneration In Rcs Rats. Invest. Ophthalmol. Vis. Sci. 2011;52(14):480.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To investigate age-related differences of recovery of visual function in Royal College of Surgeons (RCS) rats which received Channelrhodopsin-2 (ChR2) gene transfer.

Methods: : An adeno-associated virus vector encoding ChR2 fused with Venus (AAV-ChR2V) was intravitreously injected into young (6 months-old) or aged RCS (10 months-old) rats. All experiments were performed after 4 months of injection. To estimate the transduction efficiencies, ChR2V-expressing cells and retrograde labeled retinal ganglion cells (RGCs) were counted. Visually evoked potentials (VEPs) were periodically recorded. The function of retinal cells was studied on frozen sections by immunostainigs of Glial fibrillary acidic protein (GFAP).

Results: : ChR2V was expressed in the RGCs of both groups, young- and aged- rats, and there was no significant difference in the transduction efficiency between groups. However, the number of RGCs in aged RCS rats was significantly less than that in young RCS rats. In addition, the amplitudes and latencies from young RCS rats were higher and shorter, respectively, than those from aged RCS rats. High immunoreactivity of GFAP was observed in no-treated RCS rats and their immunoreactivity was strengthened according to the age, whereas immunoreactivity in ChR2V-treated RCS rats was weaker than those of no-treated rats. There were differences in expression profiles between no-treated and ChR2V-treated RCS rats. In no-treated RCS rats, GFAP immuno-reactivity was observed in INL and the IPL in addition to the staining of the ILM. On the other hand, in the ChR2-treated RCS, the immunoreactivity was restricted in ILM.

Conclusions: : ChR2 transduction produced photosensitive RGCs in both young and aged rats. Histological studies showed that expression of ChR2 had some protective effects on inner retinal neurons. These results demonstrated that the degree of recovery depended on the age at the time of transduction.

Keywords: gene transfer/gene therapy • photoreceptors • regeneration 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×